Public comment period · §3
Draft monograph: Exenatide — disposition
The disposition of every submission and the amendments that resulted.
§3Disposition and amendments
§3.1Disposition table
Table 1. Every submission with its disposition. Each row links to the submission in full.
| Reference | Respondent | Point raised | Disposition |
|---|---|---|---|
| DRAFT-EXENATIDE-MO/001 | Dr Quentin Gwynne-Sarpong | The document set should be published in translation | Not accepted |
| DRAFT-EXENATIDE-MO/002 | Dr Piotr Hollingworth | Evidence for one member of the class is presented as evidence for this compound | Accepted |
| DRAFT-EXENATIDE-MO/003 | Dr Frideswide Nordhagen | The interaction section lists mechanisms rather than interactions | Accepted in part |
| DRAFT-EXENATIDE-MO/004 | Dr Liesbeth Zaleski-Mbeki | The analytical section is longer than the clinical assessment it accompanies | Accepted in part |
| DRAFT-EXENATIDE-MO/005 | Professor Chukwuemeka Rasmussen-Adeyemi | What happens when the compound is stopped is not addressed | Accepted |
| DRAFT-EXENATIDE-MO/006 | Dr Leonhard Quenneville | The pharmacokinetic section does not connect half-life to the dosing schedule | Accepted |
| DRAFT-EXENATIDE-MO/007 | Dr Eamon Immelmann | The monograph does not tell a reader that two vials of the same compound may not contain the same thing | Accepted |
| DRAFT-EXENATIDE-MO/008 | Dr Matthias Wintringham industry | The monograph should reproduce the approved labelling rather than paraphrase it | Accepted in part |
| 8 submissions in total. | |||
§3.2Summary by disposition
Table 2. Counts by disposition, with the meaning of each.
| Disposition | Count | Meaning |
|---|---|---|
| Accepted | 4 | The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission. |
| Accepted in part | 3 | Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined. |
| Noted, no amendment | 0 | The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response. |
| Not accepted | 1 | The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it. |
§3.3Resulting amendments
- Evidence for one member of the class is presented as evidence for this compound — arising from DRAFT-EXENATIDE-MO/002. Class-level inferences are now labelled at the point of use, are excluded from the certainty rating for the compound, and are reported in a separate subsection stating which compound the underlying evidence concerns.
- The interaction section lists mechanisms rather than interactions — arising from DRAFT-EXENATIDE-MO/003. The interaction section is now divided into interactions reported in clinical use and interactions predicted from mechanism, with the second labelled as prediction. Where neither exists the section says so in one line rather than being padded.
- The analytical section is longer than the clinical assessment it accompanies — arising from DRAFT-EXENATIDE-MO/004. The analytical section is reduced to compound-specific content and cross-references the relevant standards for the general procedure, which shortens it substantially without removing what is not available elsewhere.
- What happens when the compound is stopped is not addressed — arising from DRAFT-EXENATIDE-MO/005. Discontinuation trajectory is now an assessed outcome in every monograph where a contributing trial measured it, and a recorded evidence gap in every monograph where none did, so that its absence is visible rather than silent.
- The pharmacokinetic section does not connect half-life to the dosing schedule — arising from DRAFT-EXENATIDE-MO/006. The pharmacokinetic section now states approximate time to steady state alongside the half-life and dosing interval, with the assumption of first-order elimination stated, and records where the assumption is not supported for this compound.
- The monograph does not tell a reader that two vials of the same compound may not contain the same… — arising from DRAFT-EXENATIDE-MO/007. A standing paragraph now appears at the head of §8 in every monograph, stating that a determination applies to the lot measured and that a label mass is not a determination.
- The monograph should reproduce the approved labelling rather than paraphrase it — arising from DRAFT-EXENATIDE-MO/008. The approved indication and contraindications are now reproduced verbatim from the named authorisation with its version and date, and the posology section reports the labelled schedule and the schedules studied side by side, with the source of each stated.
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.
Compound Evidence Institute · CEI-CP-049/3 · https://compoundevidence.com/comment-periods/draft-exenatide-monograph/disposition/ · retrieved 30 July 2026